le-vel glp-1 THRIVE myGLP Jorrwatee GLP-1 Supplements Women &

Patients receiving liraglutide injection in combination with an insulin secretagogue (e.g., sulfonylurea) or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia

This study demonstrated a significant improvement in glycemic control after 26 weeks without clinically significant effects on the incidence of hypoglycemia, which occurred most often in patients who also were taking a sulfonylurea [21]

[PubMed] 6

Oral semaglutide 2550 mg produces the largest average reduction, followed by orforglipron closely behind ( Nausea and vomiting increase with higher semaglutide exposure, with the 50 mg oral dose showing the greatest frequency, especially during dose escalation

Genetic factors also play a role in how individuals mount antifungal immune responses and metabolize glucose